HemOnc Today New York

Healio.com brings you the highlights from HemOnc Today New York. Refer back to this page often to read the latest news, see perspectives and interviews with leading researchers and clinicians, and review archives of past meetings.
Video

VIDEO: New data emerges for adjuvant treatment of melanoma

March 10, 2018
NEW YORK — In this video commentary from HemOnc Today New York, co-program chair Sanjiv S. Agarwala, MD, summarizes highlights from the…
Meeting NewsVideo

VIDEO: CAR T-cell therapy has ‘incredible potency’ in chronic lymphocytic leukemia

March 10, 2018
NEW YORK — In this video commentary from HemOnc Today New York, co-program chair David L. Porter, MD, discussed the use of chimeric antigen…
Meeting News

CAR T-cell therapy ‘holds great promise’ for advanced chronic lymphocytic leukemia

March 10, 2018
NEW YORK — Chimeric antigen receptor T-cell therapy “holds great promise” for patients with advanced relapsed or refractory chronic…
Meeting NewsVideo

VIDEO: Onset, frequency of toxicities vary between CTLA-4, PD-L1 agents

March 9, 2018
NEW YORK — In this video commentary from HemOnc Today New York, Young Kwang Chae, MD, MPH, MBA, discussed
Meeting NewsVideo

VIDEO: New data emerges for immunotherapy in frontline treatment of advanced lung cancer

March 9, 2018
NEW YORK — In this video commentary from HemOnc Today New York, Taofeek K. Owonikoko, MD, PhD, discussed the existing and emerging evidence of…
Meeting News

Treatment of recurrent or metastatic head and neck cancer remains challenging

March 9, 2018
NEW YORK — Treatment of recurrent or metastatic head and neck cancer is challenging given the availability of only a few treatment options…
Meeting News

Salvage immunotherapy viable for non-small cell lung cancer

March 9, 2018
NEW YORK — Immunotherapy remains a viable option for pretreated patients with non-small cell lung cancer, but the data are rapidly evolving…

Collaboration essential for management of immunotherapy toxicities

March 9, 2018
NEW YORK — Immunotherapy-related toxicities can be identified through careful monitoring and physicians should collaborate with other…
Meeting News

Real-world data can guide decisions about which patients should receive immunotherapy

March 9, 2018
NEW YORK — The pool of patients eligible to receive immunotherapy likely should include many individuals who were excluded from early…
Meeting News

High microsatellite instability, mutation load may predict checkpoint inhibitor response

March 8, 2018
NEW YORK — Pembrolizumab and nivolumab demonstrated considerable activity in patients with tumors with high levels of microsatellite…